4
Changes in Ownership
Mineralys Therapeutics, Inc. Filed Acc 0001933414-25-000150
Director sold 15,000 shares at an average $45.99 ($689,797)
- Director acquired 15,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Karydas Daphne Director | 2025-11-13 | Option exercise | +15,000 | $10.20 | $153,000 | 15,000 | D |
| Karydas Daphne Director | 2025-11-13 | Sale | −10,115 | $45.81 | $463,351 | 4,885 | D |
| Karydas Daphne Director | 2025-11-13 | Sale | −4,885 | $46.36 | $226,446 | 0 | D |
| Derivatives | |||||||
| Karydas Daphne Director | 2025-11-13 | Option exercise · Stock Option | −15,000 | 17,900 | D | ||
| Open-market sales · 15,000 sh · avg $45.99 · $689,797 | |||||||
Loading xslF345X05/wk-form4_1763078481.xml…